New study: early-stage MGUS/SMM/CLL patients test arabinoxylan rice bran and curcumin

This study was carried out on cells, though, not human beings. But today, about five years later, we have the results of a small study carried out on 20 curcumin-taking human beings with stable, early-stage MGUS, SMM, and CLL (chronic lymphocytic leukemia). And it’s a Terry Golombick (et al) study, to boot. Here’s the link to the full study, which is available for free online (love that!): http://goo.gl/6n2X3U The Golombick team tested Ribraxx, a combination of a rice bran and shiitake mushroom extract (too bad it isn’t chocolate with almonds!!!), together with a form of C3 Complex curcumin called Curcuforte (which I’d never heard of before…it’s made by an Australian company), on a group of 10 MGUS/SMM patients and 10 CLL patients. At a certain point, they mention a  previous study, which I missed (!) but will go read tomorrow, on 48 myeloma patients who took two grams of this Ribraxx per day. The results were: increased NK (natural killer) cell activity, increased levels of mDCs (myeloid dendritic cells) in the peripheral blood and of Th-1-related cytokines. Yes, definitely need to check this out… But right now I have time only for the Golombick study. The MGUS/SMM/CLL patients took a daily dose of six grams of Curcuforte and two grams of Ribraxx, in divided doses. The study monitored a whole bunch of markers, including CRP, FBC, paraprotein, ESR, B2M and so on. You can read about the markers on page 3, in the “Resul...
Source: Margaret's Corner - Category: Cancer & Oncology Authors: Tags: Blogroll Golombick Source Type: blogs